Viking Therapeutics, Inc. (VKTX) Stock
Fundamentals
Source: third-party data provider, as of October 12, 2026
Compare with VKTX
Recent news

VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
VKTX

LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
VKTX

Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?
Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?
VKTX

Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
VKTX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 40.41
- MACD 12/26/9
- -1.33
- EMA 9 of MACD
- -0.76
- MACD histogram
- -0.57
- SMA 50
- $32.79
- Price below SMA 50
- EMA 50
- $32.53
- Price below EMA 50
- SMA 200
- $33.01
- Price below SMA 200
- EMA 200
- $33.35
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$1.03 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
VKTX

LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
VKTX

Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?
Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?
VKTX

Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
VKTX

Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts
VKTX

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
VKTX

3 Emerging Biotech Stocks With Significant Upside Potential
3 Emerging Biotech Stocks With Significant Upside Potential
VKTX

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
VKTX

Dow, S&P 500, Nasdaq Futures Fall Amid Rising Bond Yields, AI Concerns: KOD, SMMT, CLF, VKTX Stocks In Focus
Dow, S&P 500, Nasdaq Futures Fall Amid Rising Bond Yields, AI Concerns: KOD, SMMT, CLF, VKTX Stocks In Focus
VKTX

VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks
VKTX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Viking Therapeutics, Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Brian Lian Ph.D. | President, CEO & Director | 1966 |
| Mr. Gregory S. Zante CPA | Chief Financial Officer | 1971 |
| Mr. Michael Morneau | Vice President of Finance & Administration | 1965 |
| Ms. Katherine Mercier | Vice President of Quality & Compliance | — |
| Mr. Kenneth J. Herman M.B.A. | Senior Vice President of Commercial, Marketing & Sales | — |
| Dr. Geoffrey E. Barker Ph.D. | Chief Development Officer | — |
| Mr. Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer | 1970 |
| Dr. Nils U. Olsson Ph.D. | Senior Vice President of Technical Operations | — |
| Dr. Hubert C. Chen M.D., M.P.H. | Chief Medical Officer | 1969 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 12, 2026
Technical indicators
- RSI 14
- 40.41
- MACD 12/26/9
- -1.33
- EMA 9 of MACD
- -0.76
- MACD histogram
- -0.57
- SMA 50
- $32.79
- Price below SMA 50
- EMA 50
- $32.53
- Price below EMA 50
- SMA 200
- $33.01
- Price below SMA 200
- EMA 200
- $33.35
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $65.00
- Average
- $88.00
- High
- $114.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -5.8 | -13.5 | -8.4 | |||||||||
| 2022 | -24.0 | -12.5 | -8.5 | -24.0 | -12.3 | +35.7 | +6.7 | +10.8 | -15.8 | +50.7 | -7.3 | +127.6 |
| 2023 | +2.8 | +25.1 | +46.2 | +21.3 | -0.7 | -26.2 | -6.1 | -2.5 | -23.7 | -9.8 | +27.7 | +43.0 |
| 2024 | +32.1 | +221.7 | -3.8 | +0.1 | -18.5 | -14.9 | +3.0 | +17.3 | +8.4 | +17.0 | -27.4 | -21.9 |
| 2025 | -20.4 | -8.4 | -6.0 | +20.7 | -6.4 | +1.5 | +22.1 | -17.2 | -4.4 | +39.1 | +2.3 | +1.8 |
| 2026 | -18.0 | +13.1 | -2.4 | -5.4 | +9.1 | +24.8 | -15.3 | +0.5 | -3.2 | -6.6 |



